30.04.2026
ALP Bio AG raises CHF 1.75 million pre-seed to de-risk antibody development
Immunogenicity, including anti-drug antibody (ADA) responses, remains one of the most difficult risks … The financing round was led by Munich-based VC 42CAP, with participation from, Ajira Ventures, Venture Kick and a group of strategic angel investors. Thomas Wilke, Partner at 42CAP, adds: “ALP Bio is doing …
> zum Detail